

Active surveillance for low-risk prostate cancer: What do we still need to know?

Poster Session 60

Monday, 27 March
12:15 - 13:45

Location: Room Madrid, North Hall (Level 1)

Chairs: A.R. Azzouzi, Angers (FR)
M.R. Cooperberg, San Francisco (US)
N. Suardi, Milan (IT)

Aims and objectives of this session

The aim of this session is to highlight lights and shadows of active surveillance and how to improve current protocols

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- 793 **The spatial distribution of positive cores predicts outcomes of active surveillance in very low risk prostate cancer patients**
By: [Erickson A.](#)¹, [Vasarainen H.](#)², [Mirtti T.](#)³, [Rannikko A.](#)²
Institutes:¹University of Helsinki, Institute for Molecular Medicine Finland, Helsinki, Finland, ²University of Helsinki, Dept. of Urology, Helsinki, Finland, ³University of Helsinki, Institute for Molecular Medicine Finland, Dept. of Pathology, Helsinki, Finland
- 794 **Variation in the use of active surveillance for low-risk prostate cancer**
By: [Löppenber B.](#)¹, [Friedlander D.](#)¹, [Tam A.](#)¹, [Von Landenberg N.](#)¹, [Gild P.](#)¹, [Leow J.](#)², [Krasnova A.](#)¹, [Kibel A.](#)¹, [Noldus J.](#)³, [Menon M.](#)⁴, [Sun M.](#)¹, [Trinh Q-D.](#)¹
Institutes:¹Brigham and Women's Hospital, Division of Urologic Surgery and Center For Surgery and Public Health, Boston, United States of America, ²Tan Tock Seng Hospital, Dept. of Urology, Singapore, Singapore, ³Marien Hospital Herne, Ruhr-University Bochum, Dept. of Urology, Herne, Germany, ⁴Henry Ford Health System, VUI Center for Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Detroit, United States of America
- 795 **PTEN status in diagnostic biopsies predicts active surveillance rebiopsy Gleason upgrade, treatment change and adverse surgical histopathological findings**
By: [Erickson A.](#)¹, [Lokman U.](#)², [Vasarainen H.](#)², [Mirtti T.](#)³, [Rannikko A.](#)²
Institutes:¹University of Helsinki, Institute for Molecular Medicine Finland, Helsinki, Finland, ²University of Helsinki, Dept. of Urology, Helsinki, Finland, ³University of Helsinki, Dept. of Pathology, Institute for Molecular Medicine Finland, Helsinki, Finland
- 796 **Risk-based selection for active surveillance: Results of the Movember Foundation's Global Action Plan prostate cancer active surveillance (GAP3) initiative**
By: [Nieboer D.](#)¹, [Steyerberg E.](#)¹, [Bruinsma S.](#)², [Bangma C.](#)², [Roobol M.](#)²
Institutes:¹Erasmus MC, Dept. of Public Health, Rotterdam, The Netherlands, ²Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands
- 797 **Pathological findings at radical prostatectomy after initial active surveillance in low-risk prostate cancer patients. Did we miss the chance to cure?**
By: [Suardi N.](#)¹, [Luzzago S.](#)¹, [Dell'Oglio P.](#)¹, [Fossati N.](#)¹, [Gandaglia G.](#)¹, [Zaffuto E.](#)¹, [Gaboardi F.](#)¹, [Doglioni C.](#)², [Freschi M.](#)², [Scattoni V.](#)¹, [Stabile A.](#)¹, [Montorsi F.](#)¹, [Briganti A.](#)¹
Institutes:¹Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ²Vita-Salute University San Raffaele, Dept. of Pathology, Milan, Italy
- 798 **Outcomes after deferred radical prostatectomy for men initially managed with active surveillance**

By: Arnsrud Godtman R.¹, Schafferer M.², Stranne J.², Hugosson J.²

Institutes:¹Institute of Clinical Sciences, Sahlgrenska Academy At The University of Göteborg, Dept. of Urology, Gothenburg, Sweden, ²Institute of Clinical Sciences, Sahlgrenska Academy At The University of Gothenburg, Dept. of Urology, Gothenburg, Sweden

799

Compliance of prostate cancer patients on active surveillance to protocol criteria: The experience of a large mono-institutional population

By: Badenchini F.¹, Palorini F.¹, Alvisi M.F.¹, Marengi C.¹, Tulli Baldoïn E.¹, Nicolai N.², Salvioni R.², Catanzaro M.², Stagni S.², Tesone A.², Torelli T.², Villa S.³, Bedini N.⁴, Avuzzi B.⁴, Morlino S.⁴, Colecchia M.⁵, Messina A.⁶, Bellardita L.¹, Magnani T.¹, Rancati T.¹, Valdagni R.⁷

Institutes:¹Fondazione IRCCS Istituto Nazionale Tumori, Prostate Cancer Program, Milan, Italy, ²Fondazione IRCCS Istituto Nazionale Tumori, Dept. of Urology, Milan, Italy, ³Fondazione IRCCS Istituto Nazionale Tumori, Dept. of Radiation Oncology, Milan, Italy, ⁴Fondazione IRCCS Istituto Nazionale Tumori, Dept. of Radiation Oncology, Milan, Italy, ⁵Fondazione IRCCS Istituto Nazionale Tumori, Dept. of Anatomic-Pathology, Milan, Italy, ⁶Fondazione IRCCS Istituto Nazionale Tumori, Dept. of Radiology, Milan, Italy, ⁷Università Degli Studi Di Milano & Fondazione IRCCS Istituto Nazionale Tumori, Dept. of Hematology and Hemato-Oncology & Prostate Cancer Program & Radiation Oncology, Milan, Italy

800

Variation in prostate cancer care at commission on cancer designated facilities

By: Löppenberg B.¹, Sood A.², Deepansh D.², Karaborn P.³, Sammon J.⁴, Vetterlein M.⁵, Noldus J.¹, Peabody J.², Trinh Q-D.⁶, Menon M.², Abdollah F.²

Institutes:¹Ruhr-University Bochum, Marien Hospital Herne, Dept. of Urology, Herne, Germany, ²Center For Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Henry Ford Hosp, Dept. of Urology, Detroit, United States of America, ³Henry Ford Hospital, Dept. of Public Health Sciences, Detroit, United States of America, ⁴Maine Medical Center, Division of Urology & Center For Outcomes Research, Portland, United States of America, ⁵University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, United States of America, ⁶Center For Surgery and Public Health, Brigham and Women's Hospital, Division of Urology, Boston, United States of America

801

Multiparametric MRI represents an added value but not a substitute of follow-up biopsies in patients on active surveillance for low-risk prostate cancer

By: Luzzago S.¹, Suardi N.¹, Dell'Oglio P.¹, Cardone G.², Gandaglia G.¹, Esposito A.², De Cobelli F.², Cristel G.², Kinzikeeva E.¹, Freschi M.³, Gaboardi F.¹, Del Maschio A.², Montorsi F.¹, Briganti A.¹

Institutes:¹Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ²Vita-Salute University San Raffaele, Dept. of Radiology, Milan, Italy, ³Vita-Salute University San Raffaele, Dept. of Pathology, Milan, Italy

802

Introducing mpMRI into contemporary UK active surveillance for localised prostate cancer

By: Bryant R.¹, Yang B.¹, Philippou Y.¹, Lam K.¹, Obiakor M.¹, Ayers J.B.¹, Gleeson F.², Macpherson R.², Verrill C.³, Roberts I.³, Leslie T.¹, Crew J.¹, Sooriakumaran P.¹, Hamdy F.¹, Brewster S.¹

Institutes:¹Oxford University Hospitals Nhs Foundation Trust, Dept. of Urology, Oxford, United Kingdom, ²Oxford University Hospitals Nhs Foundation Trust, Dept. of Radiology, Oxford, United Kingdom, ³Oxford University Hospitals Nhs Foundation Trust, Dept. of Pathology, Oxford, United Kingdom

*803

MRI as a follow up tool in active surveillance – results from an MRI-defined active surveillance cohort (387 men, median 5 year follow up)

By: Retter A.¹, Giganti F.¹, Kirkham A.¹, Allen C.¹, Punwani S.¹, Emberton M.², Moore C.²

Institutes:¹University College London Hospital, Dept. of Radiology, London, United Kingdom, ²University College London Hospital, Dept. of Urology, London, United Kingdom

*804

Metastases and death after 15 year of follow-up in men with screen-detected low-risk prostate cancer treated with protocol based active surveillance, radical prostatectomy or radiotherapy

By: Verbeek J., Drost F-J., Bangma C., Roobol M.

Institutes:Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands

13:30 - 13:37

Summary

To be confirmed